Immunotherapy and Asthma in Children

MINI REVIEW ARTICLE

Maria A. Tosca1*Amelia Licari2Roberta Olcese1Gianluigi Marseglia2Oliviero Sacco3 and Giorgio Ciprandi4
1Department of Pediatrics, Allergy Center, Istituto Giannina Gaslini (IRCCS), Genoa, Italy
2Department of Pediatrics, Ospedale San Matteo (IRCCS), Pediatrics Clinic, University of Pavia, Pavia, Italy
3Pediatric Pulmonology and Endoscopy, Istituto Giannina Gaslini (IRCCS), Genoa, Italy
4Allergy Clinic, Ospedale San Martino (IRCCS), Genoa, Italy

Allergen immunotherapy (AIT) is still the only disease-modifying treatment strategy for IgE-mediated allergic diseases, with consolidated evidence both in adults and children. AIT is effective in determining clinical improvement of allergic rhinitis and asthma, such as reduced symptoms, medication use, and improvement of quality of life, with a long-lasting effect after cessation of treatment. Results from recent clinical studies have implemented the evidence of effectiveness and safety of allergen immunotherapy for the treatment of allergic asthma, so that the current asthma guidelines now recommend sublingual immunotherapy as an add-on therapy for asthma in adults and adolescents with house dust mite allergy, allergic rhinitis, and exacerbations despite low-to-moderate dose ICS, with forced expiratory volume in 1 second more than 70% predicted. AIT may also reduce the risk of progression from allergic rhinitis to asthma in children and prevent the onset of new sensitizations, thus representing a potentially preventive method of treatment. The aim of this review is to present an updated overview of the clinical indications of AIT, with particular reference to pediatric asthma, of the mechanisms of clinical and immunological tolerance to allergens, and of the potential biomarkers predicting clinical response.


Download Article

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Data Sharing Report | Asthma UK https://t.co/LjNWghYL44, see more https://t.co/CpGiFuOOYd
13hreplyretweetfavorite
Interasma RT @AllergyEaaci: Advances in managing COPD related to α1‐antitrypsin deficiency: An under‐recognized genetic disorder. Download Article He…
15hreplyretweetfavorite
Interasma RT @Aller_MD: My Tweeted Times https://t.co/36WLWcQjoy - top stories by @GavinPrestonMD, @CleanAirLondon
15hreplyretweetfavorite
Interasma RT @Aller_MD: NIH, Children's National Health System join forces to study pediatric disease https://t.co/vdbhviWhMF
15hreplyretweetfavorite
Interasma RT @eaaci_patients: AAAAI & EAACI answer your questions on asthma and air quality. Save the date and join the Twitter chat on 27 September…
15hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma